PROMOTING ACCESS TO AFRICAN RESEARCH

African Journal of Infectious Diseases

The AJOL site is currently undergoing a major upgrade, and there will temporarily be some restrictions to the available functionality.
-- Users will not be able to register or log in during this period.
-- Full text (PDF) downloads of Open Access journal articles will be available as always.
-- Full text (PDF) downloads of subscription based journal articles will NOT be available
We apologise for any inconvenience caused. Please check back soon, as we will revert to usual policy as soon as possible.





The role of an aggressive factor in peptic ulcer disease (pud)

R.A Magaji, Y Tanko, G.M Magaji

Abstract


The stomach is the expanded part of the digestive tract between the esophagus and the small intestine. It acts as a reservoir and has chief function in enzymatic digestion. Several types of glands provide different types of secretions in the alimentary tract most of which act as lubricant and to protect the stomach mucosa from excoriation.
The pathophysiology of peptic ulcer disease (PUD) is often described as an imbalance between aggressive factors and mucosal protective mechanisms. Helicobacter pylori, a gram-negative organism that has been identified as a potential causative agent in the pathogenesis of peptic ulcer disease, which is diagnosed by invasive or non-invasive
methods. Three classes of drugs have been shown to have a direct effect on Helicobacter pylori: antibiotics, bismuth salts, and proton pump inhibitors. Because Helicobacter pylori is difficult to eradicate, most treatment regimes combine agents from two or even all three of these cases. In all of them, patients with active peptic disease should
also receive a total of 6 weeks of acid suppression with an H2-receptor antagonist. The discovery of Helicobacter pylori as a gastrointestinal pathogen has had a profound effect on current concepts of the pathogenesis and treatment of peptic ulcer disease.

 

Key words: peptic ulcer disease, Helicobacter pylori, H2-receptor antagonist, pathophysiology




http://dx.doi.org/10.4314/ajid.v2i2.55068
AJOL African Journals Online